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Abstract
Non-alcoholic fatty liver disease (NAFLD) is closely associated with obesity and insulin resistance. To better understand the
pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in
metformin actions on reducing hepatic steatosis and inflammation during obesity. C57BL/6J mice were fed a high-fat diet
(HFD) for 12 weeks to induce obesity-associated NAFLD and treated with metformin (150 mg/kg/d) orally for the last four
weeks of HFD feeding. Compared with HFD-fed control mice, metformin-treated mice showed improvement in both
glucose tolerance and insulin sensitivity. Also, metformin treatment caused a significant decrease in liver weight, but not
adiposity. As indicated by histological changes, metformin treatment decreased hepatic steatosis, but not the size of
adipocytes. In addition, metformin treatment caused an increase in the phosphorylation of liver AMP-activated protein
kinase (AMPK), which was accompanied by an increase in the phosphorylation of liver acetyl-CoA carboxylase and decreases
in the phosphorylation of liver c-Jun N-terminal kinase 1 (JNK1) and in the mRNA levels of lipogenic enzymes and
proinflammatory cytokines. However, metformin treatment did not significantly alter adipose tissue AMPK phosphorylation
and inflammatory responses. In cultured hepatocytes, metformin treatment increased AMPK phosphorylation and
decreased fat deposition and inflammatory responses. Additionally, in bone marrow-derived macrophages, metformin
treatment partially blunted the effects of lipopolysaccharide on inducing the phosphorylation of JNK1 and nuclear factor
kappa B (NF-kB) p65 and on increasing the mRNA levels of proinflammatory cytokines. Taken together, these results
suggest that metformin protects against obesity-associated NAFLD largely through direct effects on decreasing hepatocyte
fat deposition and on inhibiting inflammatory responses in both hepatocytes and macrophages.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is defined by fat
deposition in hepatocytes (hepatic steatosis). In generally accepted
concepts, NAFLD is comprised of simple steatosis, which may be
benign, and non-alcoholic steatohepatitis (NASH), which is the
advanced form of NAFLD. Simple steatosis progresses to NASH
when the liver develops overt inflammation and necrotic damage
that are not associated with alcohol consumption. It is now
recognized that NASH is a leading causal factor of cirrhosis and
hepatocellular carcinoma [1,2]. Additionally, hepatic steatosis is a
major contributor of dyslipidemia that works with or without
insulin resistance to significantly increase the incidence of
atherogenic cardiovascular diseases [3]. Given this, a better
understanding of how to reduce hepatic steatosis and how to
decrease liver inflammation are of critical importance in effectively
managing NAFLD and fatty liver-associated metabolic and
inflammatory diseases.
Because NAFLD is highly prevalent in obese populations [4],
obesity-associated insulin resistance is considered as a factor
that critically contributes to the development of NAFLD. Mecha-
nistically, insulin resistance at both hepatic and systemic levels,
along with hyperinsulinemia, acts to increase the expression of
genes for lipogenic enzymes such as acetyl-CoA carboxylase 1
(ACC1) and fatty acid synthase (FAS) [5,6] and to decrease the
expression of genes for fatty acid oxidation including carnitine
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palmitoyltransferase 1a (CPT1a) [7]. These changes, in turn, bring
about hepatic steatosis. As a primary ‘‘hit’’, fat deposition is sufficient
to trigger the inflammatory responses as indicated by the results from
cultured hepatocytes [8,9]. As another key characteristic of obesity,
adipose tissue dysfunction has also been implicated in the
development of NAFLD. Indeed, this role of dysfunctional adipose
tissue is highlighted by the ‘‘second hit’’ hypothesis. In support of
this, adipocyte-specific overexpression of monocyte chemoattractant
protein-1 (MCP1), an inflammatory molecule up-regulated in
adipose tissue of obese mice and human subjects, mediates the
effect of adipose tissue inflammation to bring about an increase in
hepatic triglyceride content [10]. These results and many others
suggest that dysfunctional adipose tissue contributes to hepatic
steatosis by increasing the delivery of fatty acid flux to the liver [2]
and by impairing liver insulin signaling through adipose tissue-
driven inflammation [11,12]. Currently, a number of approaches
that are capable of improving insulin sensitivity and adipose tissue
functions, i.e., weight loss, metformin treatment, and insulin
sensitization by thiazolidinediones (TZDs), have been considered
for managing NAFLD [1,13–15].
Metformin is a widely used anti-diabetic medicine that
effectively lowers plasma glucose levels primarily by decreasing
hepatic glucose production (HGP) and by improving lipid
metabolism in both liver and muscle tissues [16–19]. At the
cellular level, metformin activates AMP-activated protein kinase
(AMPK). This serves as a key mechanism by which metformin
treatment brings about a wide range of metabolic benefits [20].
Recent evidence also suggests that metformin is capable of
inhibiting hepatic gluconeogenesis, a key flux whose increase
contributes to elevation of HGP and hyperglycemia, through
pathway(s) other than AMPK [21,22]. Although the mechanisms
underlying metformin actions are more complicated than what
were thought before, there is accumulating evidence that
demonstrates the beneficial effects of metformin treatment on
improving hepatic steatosis and on inhibiting liver inflammation
[13,23]. At the systemic level, however, it remains to be a critical
need to explore the extent to which the anti-NAFLD effects of
metformin are related to alternations in both the liver and adipose
tissue. Accordingly, it was hypothesized that metformin protects
against NAFLD through direct effects on liver metabolic and
inflammatory responses and through an indirect effect on
improving adipose tissue phenotype. The results of the present
study support that metformin acts directly to improve hepatocyte
fat metabolism and to suppress inflammatory responses of both
hepatocytes and macrophages. Interestingly, the protective role of
metformin in reducing obesity-associated hepatic steatosis and
inflammation appears to be independent of alterations in adipose
tissue phenotype.
Results
Metformin treatment ameliorates HFD-induced systemic
insulin resistance and glucose intolerance
C57BL/6J mice were fed a high-fat diet (HFD) for 12 weeks to
induce obesity (diet-induced obesity, DIO). Compared with age-
and gender-matched mice that were fed a low-fat diet (LFD),
HFD-fed and phosphate-buffered saline (PBS)-treated mice
exhibited a marked increase in body weight (Figure 1A), as well
as overt hepatic steatosis and increased liver inflammatory
responses (see below, Figures 2 and 3). These results demonstrate
the establishment of NAFLD in obese mice. In addition, HFD-fed
and PBS-treated mice displayed a significant increase in the
severity of insulin resistance and glucose intolerance (Figure 1, C
and D) compared with LFD-fed and PBS-treated mice. Upon
treatment with metformin, body weight of HFD-fed mice
remained the same compared with HFD-fed and PBS-treated
mice. Also, metformin treatment did not alter food intake of HFD-
fed mice (Figure 1B, HFD-Met vs. HFD-PBS). However,
metformin-treated mice showed a significant decrease in the
severity of HFD-induced insulin resistance and glucose intolerance
(Figure 1, C and D), which were indicated by changes in plasma
levels of glucose in response to a peritoneal injection of insulin and
glucose, respectively. Thus, treatment with metformin ameliorates
HFD-induced systemic insulin resistance and glucose intolerance
without altering body weight in DIO mice.
Metformin treatment decreases HFD-induced hepatic
steatosis and increases liver AMPK phosphorylation
NAFLD is commonly associated with obesity. Consistent with
increased body weight, liver weight of HFD-fed and PBS-treated
mice was much greater than that of LFD-fed mice (Figure 2A).
Additionally, HFD-fed and PBS-treated mice displayed severe
hepatic steatosis indicated by changes in liver sections stained with
hematoxylin and eosin (H&E) and/or Oil-Red-O (Figure 2B).
Given this, HFD-fed mice, serving as a mouse model of NAFLD,
were used to examine the therapeutic effects of metformin, as well
as the underlying mechanisms. Compared with HFD-fed and
PBS-treated mice, HFD-fed and metformin-treated mice exhibited
a significant decrease in liver weight (Figure 2A), which was
accompanied by a marked decrease in the severity of hepatic
steatosis (Figure 2B). Thus, treatment with metformin effectively
ameliorates hepatic steatosis in obese mice. We next examined
changes in liver AMPK phosphorylation, which may underlie the
beneficial effects of metformin. Compared with LFD-fed and PBS-
treated mice, HFD-fed and PBS-treated mice showed a significant
decrease in liver AMPK phosphorylation (Figure 2C). This
decrease was reversed by treatment with metformin as this was
supported by the finding that liver AMPK phosphorylation in
HFD-fed and metformin-treated mice was much greater than that
in HFD-fed and PBS-treated mice (Figure 2C). Consistently, the
phosphorylation of ACC, a substrate enzyme of AMPK, was
decreased in HFD-fed and PBS-treated mice compared with that
in LFD-fed mice. Upon treatment with metformin, liver ACC
phosphorylation in HFD-fed mice was significantly increased
compared with that of HFD-fed and PBS-treated mice (Figure 2C).
We also examined changes in the mRNA levels of key enzymes
that critically control the development of hepatic steatosis from
livers of HFD-fed mice. In terms of regulating hepatic gene
expression, the effects of HFD feeding have been previously
studied in rodents by a number of investigators. However, HFD
feeding increases liver FAS mRNA levels when compared with a
chow diet [24,25] and decreases liver FAS mRNA levels when
compared with LFD feeding [26,27]. Additionally, HFD feeding
appears to have limited effects on liver expression of ACC and
sterol regulatory element-binding protein 1c (SREBP1c), the latter
is a transcription factor whose active form stimulates hepatic
expression of lipogenic enzymes including ACC and FAS. In the
represent study, we confirmed that HFD feeding decreased liver
mRNA levels of FAS compared with LFD feeding. Meanwhile,
HFD feeding did not significantly alter the mRNA levels of ACC
and SREPBP1c. However, within all HFD-fed mice, treatment
with metformin caused a significant decrease in the mRNA levels
of ACC1 and FAS compared with PBS (Figure 2D). These results,
together with decreased phosphorylation of liver ACC in
metformin-treated mice, suggest a likely decrease in hepatic
lipogenesis, which is consistent with the outcome of increased
hepatic AMPK phosphorylation. Compared with LFD-fed and
PBS-treated mice, HFD-fed and PBS-treated mice also displayed a
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decrease in liver mRNA levels of CPT1a, a rate-determining
enzyme that transfers long-chain fatty acids into mitochondria for
oxidation. Within HFD-fed mice, treatment with metformin
tended to increase liver mRNA levels of CPT1a, but the increase
was not statistically significant. Collectively, these results suggest
that metformin ameliorates HFD-induced hepatic steatosis, and
this effect of metformin is associated with an increase in liver
AMPK phosphorylation.
Metformin treatment inhibits HFD-induced liver
inflammatory responses
Inflammation is the key factor that drives the progression of
simple steatosis to NASH. We examined the content of
macrophages/Kupffer cells (F4/80+ cells) in livers of the mice.
Unlike adipose tissue which displays a marked increase in
macrophage infiltration in response to HFD feeding as established
by many publications, livers of HFD-fed and PBS-treated mice
contained fewer numbers of F4/80+ cells (Figure 3A, quantitative
data not shown). Also, treatment with metformin tended to
increase liver content of F4/80+ cells. These results suggest that
liver content of F4/80+ cells is not an ideal indicator of liver
inflammatory responses. We then examined liver inflammatory
signaling through JNK and NF-kB p65 and quantified the mRNA
levels of proinflammatory cytokines to assess liver inflammatory
responses. Compared with that in livers of LFD-fed and PBS-
treated mice, the phosphorylation of JNK1 (p46) in livers of HFD-
fed and PBS-treated mice was significantly increased (Figure 3B).
A similar trend was also observed in the phosphorylation of NF-kB
p65 (Ser536) in livers of HFD-fed and PBS-treated mice compared
with LFD-fed controls; although this trend did not reach statistical
significance. Upon treatment with metformin, the phosphorylation
of liver JNK1 (p46) was significantly decreased compared with that
of HFD-fed and PBS-treated mice (Figure 3B). When liver mRNA
levels of proinflammatory cytokines were examined, HFD-fed and
PBS-treated mice displayed a significant increase in the mRNA
levels of interleukin-6 (IL-6), a proinflammatory cytokine that is
abundantly expressed in hepatocytes; although HFD-fed and PBS-
treated mice showed a decrease in liver mRNA levels of IL-1b and
tumor necrosis factor a (TNFa) compared with LFD-fed and PBS-
treated mice. Within all HFD-fed mice, treatment with metformin
significantly decreased liver mRNA levels of IL-6, as well as IL-1b
and TNFa compared with PBS (Figure 3C). Together, these
results suggest that metformin decreases liver inflammatory
responses while improving hepatic steatosis in DIO mice.
Metformin treatment does not alter HFD-induced
adiposity and adipose tissue inflammatory responses
During obesity, dysfunctional adipose tissue critically contrib-
utes to the development of NAFLD [12]. We examined changes in
adipose tissue phenotype. Consistent with DIO, all HFD-fed mice
displayed a marked increase in visceral fat mass compared with
LFD-fed mice (data not shown). Following treatment with
metformin, HFD-fed mice did not display significant changes in
visceral fat mass compared with HFD-fed and PBS-treated mice.
Additionally, the size of adipocytes in HFD-fed and metformin-
treated mice did not differ from that in HFD-fed and PBS-treated
mice indicated by adipose tissue histology (Figure 4A). Thus,
treatment with metformin did not alter HFD-induced adiposity.
Figure 1. Metformin treatment ameliorates HFD-induced insulin resistance and glucose intolerance. Male C57BL/6J mice, at 5–6 weeks
of age, were fed a high-fat diet (HFD) and treated with metformin (Met, 150 mg/kg body weight/d, in phosphate-buffered saline (PBS)) or PBS for the
last 4 weeks of HFD feeding. As an additional control, gender- and age-matched mice were fed a low-fat diet (LFD) for 12 weeks and treated only with
PBS for the last 4 weeks. Data are means 6 SE, n = 6–10. (A) Body weight was monitored weekly during the feeding/treatment regimen. (B) Food
intake was calculated based on food consumption per day per mouse. (C) Insulin tolerance tests (ITT). (D) Glucose tolerance tests (GTT). For C and D,
mice were fasted for 4 hr and received an intraperitoneal injection of insulin (1 U/kg body weight) (C) or glucose (2 g/kg body weight) (D). *, P,0.05
and **, P,0.01 HFD-Met vs. HFD-PBS for the same time point (C and D).
doi:10.1371/journal.pone.0091111.g001
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We next examined adipose tissue inflammatory responses. As
indicated by percentages of mature macrophages (F4/80+ CD11b+
cells) from the isolated adipose tissue stromal vascular cells (Figure
S1, A and B in File S1), adipose tissue macrophage infiltration in
HFD-fed and PBS-treated mice was markedly increased compared
with that in LFD-fed and PBS-treated mice (Figure S1C in File
S1). However, within HFD-fed mice, treatment with metformin
did not significantly alter adipose tissue macrophage infiltration
(Figure 4C and Figure S1C in File S1). These results were
consistent with the finding that adipose tissue content of F4/80+
cells in HFD-fed and metformin-treated mice did not differ from
that in HFD-fed and PBS-treated mice (Figure 4B). Further
analyses indicated that the percentages of proinflammatory
macrophages (F4/80+ CD11b+ CD11c+ CD2062 cells) among
mature adipose tissue macrophages in HFD-fed and metformin-
treated mice also did not differ from those in HFD-fed and PBS-
treated mice (data not shown). Unlike changes in liver AMPK
signaling, adipose tissue AMPK signaling (phosphorylation) was
not altered by metformin. Additionally, metformin treatment did
not alter adipose tissue inflammatory signaling, indicated by the
phosphorylation of JNK1 (p46) and NF-kB p65 (Ser536)
(Figure 4D). When proinflammatory cytokine expression was
examined for HFD-fed mice, treatment with metformin did not
significantly alter adipose tissue mRNA levels of IL-1b, IL-6, and
TNFa (Figure 4E), as well as mRNA levels of arginase 1,
adiponectin, and resistin, which all are related to adipose tissue
inflammation and function. Therefore, treatment with metformin
for 4 weeks appears to have limited effects on altering adipose
tissue phenotype in obese mice, indicated by adiposity and
inflammatory responses.
Metformin treatment inhibits hepatocyte fat deposition
and inflammatory responses
As indicated by the results listed above (Figures 2, 3, 4), the liver
is the primary target through which metformin ameliorates
NAFLD in obese mice. We next examined the direct effects of
metformin on metabolic and inflammatory responses in H4IIE
cells, a rat hepatoma cell line commonly used as a cell model of
NAFLD [28,29]. In the absence of metformin, treatment of H4IIE
cells with palmitate induced a significant increase in fat deposition
(Figure 5A). This effect of palmitate, however, was partially
blunted by metformin treatment, indicating a direct effect of
metformin on inhibiting hepatocyte fat deposition. Consistent with
changes in hepatocyte fat deposition, the mRNA levels of ACC1
and FAS in palmitate-treated H4IIE cells were significantly
Figure 2. Metformin treatment ameliorates HFD-induced hepatic steatosis and increases liver AMPK phosphorylation. Mice were
treated as described in Figure 1. After the feeding/treatment regimen, mice were fasted for 4 hr prior to collection of tissue samples. (A) Liver weight
(n = 6–10). (B) Liver histology. Top panels, H&E staining; bottom panels, Oil-Red-O staining. (C) Liver AMPK signaling. Liver extracts were subjected to
Western blot analyses. Ratios of phosphorylated AMPK to total AMPK (P-AMPK/AMPK) and phosphorylated ACC to total ACC (P-ACC/ACC) were
quantified using densitometry and normalized to GAPDH (AU, arbitrary unit). (D) Liver mRNA levels of key lipid metabolic enzymes (genes) were
analyzed using real-time PCR. For bar graphs (A, C, and D), data are means 6 SE, n = 6–8. {, P,0.05 and {{, P,0.01 HFD-PBS or HFD-Met vs. LFD-PBS
(A, C, and D); *, P,0.05 and **, P,0.01 HFD-Met vs. HFD-PBS (A, C, and D).
doi:10.1371/journal.pone.0091111.g002
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increased compared with those in control cells (Figure 5B).
Following treatment with metformin, the stimulatory effect of
palmitate on the expression of ACC1 and FAS was blunted
(Figure 5B). In H4IIE cells, CPT1a mRNA levels were not
significantly altered by palmitate in the absence or presence of
metformin (Figure 5B). We also examined the mRNA levels of
proinflammatory cytokines. Compared with the control, the
mRNA levels of IL-6 were increased in palmitate-treated H4IIE
cells. This stimulatory effect of palmitate was completely blunted
by treatment with metformin (Figure 5B).
We examined AMPK signaling and inflammatory signaling in
H4IIE cells. Compared with that in cells treated with control (in
the absence of metformin and lipopolysaccharide (LPS)), the
phosphorylation of AMPK was increased in metformin-treated
cells (in the absence of LPS) (Figure 5C). In the presence of LPS
alone, AMPK phosphorylation was decreased compared with that
in control cells (in the absence of metformin and LPS), and this
decrease was partially reversed by treatment with metformin.
When inflammatory signaling was examined, metformin treatment
did not significantly alter the phosphorylation of JNK1 (p46) and
NF-kB p65 under the basal conditions (in the absence of LPS).
However, metformin treatment significantly blunted the effect of
LPS on increasing hepatocyte phosphorylation of JNK1 (p46) and
NF-kB p65 compared with that in control (PBS)-treated hepato-
cytes. Together, these results suggest that metformin directly
decreases hepatocyte fat deposition and suppresses hepatocyte
inflammatory responses.
Metformin treatment suppresses macrophage
proinflammatory activation
Macrophages/Kupffer cells play a critical role in controlling the
development of hepatic steatosis and inflammation [30]. We
examined a direct effect of metformin on macrophage proinflam-
matory activation. In the absence of metformin, bone marrow-
derived macrophages (BMDM) exhibited a significant increase in
the phosphorylation of both JNK1 (p46) and NF-kB p65 (Ser536) in
response to LPS stimulation (Figure 6A), indicating LPS induction
of macrophage proinflammatory activation. However, upon treat-
ment with metformin, the effect of LPS on inducing the
phosphorylation of JNK1 (p46) and NF-kB p65 (Ser536) was
partially blunted. When macrophage expression of proinflamma-
tory cytokines was analyzed, the mRNA levels of IL-1b, IL-6, and
TNFa were markedly increased in control (PBS)-treated BMDM
after LPS stimulation. However, in metformin-treated macrophag-
es, the effect of LPS on increasing proinflammatory cytokine mRNA
levels was significantly lessened (Figure 6B). Together, these results
suggest that metformin has a direct effect on inhibiting macrophage
proinflammatory activation.
Figure 3. Metformin treatment ameliorates HFD-induced liver inflammatory responses. Mice were treated as described in Figure 1. After
the feeding/treatment regimen, mice were fasted for 4 hr prior to collection of tissue samples. (A) Liver sections were stained for F4/80+ cells. (B) Liver
inflammatory signaling. Liver extracts were subjected to Western blot analyses. Ratios of phosphorylated JNK1 to total JNK1 (Pp46/p46) and
phosphorylated NF-kB p65 to total p65 (Pp65/p65) were quantified using densitometry and normalized to GAPDH. (C) Liver mRNA levels of
proinflammatory cytokines were analyzed using real-time PCR. For bar graphs (B and C), data are means 6 SE, n = 6–8. {, P,0.05 and {{, P,0.01 HFD-
PBS vs. LFD-PBS; *, P,0.05 and **, P,0.01 HFD-Met vs. HFD-PBS.
doi:10.1371/journal.pone.0091111.g003
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Discussion
On an HFD, C57BL/6J mice developed obesity-associated
insulin resistance, as well as hepatic steatosis and inflammation.
Accordingly, HFD-fed mice were used as a model of NAFLD to
assess the therapeutic effects of metformin. Consistent with the
results obtained from both human subjects and rodent models
[13,23,31], metformin treatment not only improved HFD-induced
systemic insulin resistance and glucose intolerance, but also
brought about a marked decrease in the severity of HFD-induced
hepatic steatosis and inflammation. Using in vitro systems involving
hepatocytes and macrophages, the present study demonstrates that
metformin is capable of directly decreasing hepatocyte fat
deposition and suppressing hepatocyte and macrophage inflam-
matory responses, which all are associated with increased AMPK
phosphorylation. However, metformin treatment did not alter
obesity-associated adipose tissue phenotype. Notably, HFD-
induced adiposity and adipose tissue inflammation indicated by
adipose tissue inflammatory signaling, macrophage infiltration,
and cytokine expression in metformin-treated mice did not differ
from those in control mice. Thus, the present study provides
evidence to support that metformin treatment ameliorates obesity-
associated hepatic steatosis and inflammation in a manner
independent of adipose tissue phenotype; although obesity-
associated adiposity and adipose tissue dysfunction are thought
to critically contribute to the development of NAFLD.
Metformin is considered as an activator of AMPK. The latter,
when in active form(s), exhibits an anti-lipogenic effect through
suppressing hepatic expression of lipogenic enzymes including
ACC1 and FAS [32]. In addition, active AMPK phosphorylates
and inhibits ACC1/2 [33]. This leads to a decrease in the
production of malonyl-CoA, which in turn releases the inhibitory
effect on CPT1a to favor fatty acid oxidation. In combination,
these effects of active AMPK are thought to account, to a large
extent, for metformin actions on reducing hepatic steatosis. In the
present study, two lines of evidence support that metformin acts
through stimulating AMPK phosphorylation to reduce hepatic
steatosis. Firstly, in the in vivo study, changes in liver AMPK
phosphorylation, indicative of AMPK activity, were positively
correlated with the phosphorylation of liver ACC and reversely
correlated with the degree of hepatic steatosis and with changes in
the mRNA levels of ACC1 and FAS. Secondly, using an in vitro
system in which palmitate-treated hepatocytes served as a cell
model of hepatic steatosis, the present study further supports the
direct effects of metformin on suppressing hepatocyte fat
deposition and on increasing hepatocyte AMPK phosphorylation.
In terms of regulating hepatic steatosis, liver macrophages/
Kupffer cells have been previously shown to critically control
hepatocyte fat deposition [30]. Considering this, the in vitro results
of the present study are significant in that a direct effect of
metformin on suppressing hepatocyte fat deposition likely is
sufficient enough to mediate the anti-hepatic steatosis actions of
metformin.
The present study also suggests a potential link between AMPK
and liver inflammation that is altered by metformin. In support of
this, reversal of HFD-induced decrease in AMPK phosphorylation
by metformin was accompanied by decreases in the phosphory-
lation of liver JNK1 (p46) and in the mRNA levels of
proinflammatory cytokines. This observation was consistent with
the results of a recent study in which metformin decreased liver
Figure 4. Metformin treatment does not alter HFD-induced adiposity and adipose tissue inflammation. Mice were treated as described
in Figure 1. After the feeding/treatment regimen, mice were fasted for 4 hr prior to collection of tissue samples. (A) Adipose tissue histology (H&E
staining). (B) Adipose tissue sections were stained for F4/80+ cells. (C) Adipose tissue macrophage infiltration. Percentages of mature macrophages
(F4/80+ CD11b+ cells) in adipose tissue stromal cells were calculated using FACS analyses (n = 4–6). (D) Adipose tissue AMPK signaling and
inflammatory signaling were examined using Western blot analyses (n = 4–6). (E) The mRNA levels of adipose genes were quantified using real-time
PCR (n = 4–6). For bar graphs (C and E), data are means 6 SE.
doi:10.1371/journal.pone.0091111.g004
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Figure 5. Metformin treatment blunts hepatocyte fat deposition, increases AMPK phosphorylation, and decreases inflammatory
responses. (A) Hepatocyte fat deposition. Bottom panels, cells were incubated with palmitate (Pal). (B) Hepatocyte mRNA levels were quantified
using real-time PCR. For A and B, H4IIE cells were treated with metformin (500 mM) or PBS in the presence of palmitate (250 mM) or bovine serum
albumin (BSA) for 24 hr (B) and stained with Oil-Red-O for the last 1 hr (A). (C) Hepatocyte AMPK signaling and inflammatory signaling were examined
using Western blot analyses. H4IIE cells were treated with metformin (500 mM) or PBS for 24 hr in the presence or absence of LPS (100 ng/ml) for the
last 30 min. For bar graphs (B and C), data are means 6 SE, n = 6–8. {, P,0.05 and {{, P,0.01 Pal + PBS vs. BSA + PBS (B) or LPS vs. PBS (without LPS)
under the same condition (with or without Met) (C); *, P,0.05 and **, P,0.01 Pal + Met vs. Pal + PBS (B) or Met vs. PBS (without Met) under the same
condition (with or without LPS) (C).
doi:10.1371/journal.pone.0091111.g005
Figure 6. Metformin treatment suppresses macrophage proinflammatory activation. Bone marrow-derived macrophages were treated
with metformin (500 mM) or PBS for 24 hr in the presence or absence of LPS (100 ng/ml) for the last 30 min (A) or 6 hr (B). (A) Macrophage
inflammatory signaling was examined using Western blot analyses. (B) Macrophage mRNA levels of proinflammatory cytokines were quantified using
real-time PCR. For bar graphs (A and B), data are means6 SE, n = 4–6. {{, P,0.01 LPS vs. PBS (without LPS) in the absence of metformin (A); **, P,0.01
Met vs. PBS (without metformin) in the presence of LPS (A) or Met + LPS vs. PBS + LPS (B).
doi:10.1371/journal.pone.0091111.g006
Metformin Ameliorates Fatty Liver Disease
PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e91111
inflammatory responses in mice fed both a methionine- and
choline-deficient diet (MCD) and an HFD [23]. However, the
study involving MCD/HFD-fed mice did not address how
metformin suppresses liver inflammation, which could originate
from hepatocyte fat deposition, macrophage/Kupffer cell proin-
flammatory activation, and/or adipose tissue inflammation [28–
30,34]. Because metformin did not alter HFD-induced adipose
tissue phenotype, the present study examined the direct anti-
inflammatory effects of metformin in both hepatocytes and
macrophages. Of interest, treatment with metformin partially
blunted the effect of LPS on inducing the phosphorylation of
JNK1 (p46) and NF-kB p65 and on increasing the mRNA levels of
proinflammatory cytokine(s) in cultured hepatocytes and macro-
phages. These results serve as convincing evidence to support that
metformin acts directly on both hepatocytes and macrophages/
Kupffer cells to suppress liver inflammation in obesity-associated
NAFLD. It should be noted that metformin has a direct effect on
reducing hepatocyte fat deposition as discussed above. This effect
of metformin is believed to decrease hepatocyte production
(release) of free fatty acids including palmitate, a potent
proinflammatory fatty acid [28,29]. Considering this, it is likely
that in the in vivo condition metformin actions on hepatocytes also
generate an indirect effect on macrophages/Kupffer cells (via
paracrine) to suppress liver inflammation in NAFLD. In other
words, metformin likely also acts through reducing hepatocyte fat
deposition to indirectly suppress macrophage/Kupffer cell inflam-
matory activation. Future study is needed to examine the
proportional contribution of hepatocytes vs. macrophages/Kupf-
fer cells to the anti-inflammatory effects of metformin.
As illustrated by widely accepted concepts, dysfunctional
adipose tissue during obesity contributes to the pathogenesis of
NAFLD by increasing the delivery of fatty acids and inflammatory
mediators to the liver to exacerbate hepatic fat deposition and
inflammatory responses. Because of this, we also postulated that
improved adipose tissue phenotype would contribute to the anti-
NAFLD effect of metformin. However, this was not the case. In
the present study, adipose tissue, unlike the liver, did not respond
to metformin treatment. Notably, HFD-induced adiposity and
adipose tissue inflammation in metformin-treated mice did not
differ from those in PBS-treated control mice. The underlying
mechanisms remained to be elucidated, but may be attributable to
the effect that metformin treatment did not alter adipose tissue
AMPK phosphorylation. Indeed, metformin actions on adipose
tissue phenotype remain controversial. While metformin is shown
to reduce body weight (adiposity) in both human and rodent
models, a number of papers also demonstrate that metformin does
not alter body weight, in particular in rodents fed an HFD
[18,35,36]. Additionally, the weight-loss effect of metformin is tied
closely to a decrease in food intake, leading to a question of
whether or not metformin directly acts on adipose tissue.
Considering this, the beneficial effects of metformin on features
of NAFLD appear to be due largely to the direct effects of
metformin on the liver. What should also be mentioned is that
metformin is capable of countering insulin-induced suppression of
muscle fatty acid oxidation and promoting triglyceride storage in
skeletal muscle [37]. These effects may also contribute to the
beneficial effects of metformin on features of NAFLD.
As mentioned above, metformin directly suppressed macro-
phage inflammatory activation in vitro. However, this was not the
case for the in vivo study, in which metformin treatment did not
alter the inflammatory status of adipose tissue macrophages. Given
that metformin did not alter adipose tissue AMPK, it is possible
that the treatment regimen used by the present study was not
sufficient enough for metformin to be effective in adipose tissue.
To verify this, future studies are required to include a relative long
period of time and/or a higher dose for metformin treatment.
Additional to adipose tissue inflammatory status, adiposity of
HFD-fed mice was also not reduced by metformin in the present
study. When adipose and liver tissues were compared, adipose
tissue macrophages interacted with a highly proinflammatory local
environment likely due to excessive fat deposition whereas liver
macrophages/Kupffer cells did not. Considering this, it is also
possible that a potential anti-inflammatory action of metformin on
adipose tissue macrophages was offset by the proinflammatory
effects of adipocyte-derived factors in particular saturated fatty
acids [38]. While this point needs to be further validated, it
appears to be clear that metformin primarily targets the liver to
improve features of NAFLD, and this effect of metformin is
independent of adipose tissue phenotype.
In summary, the present study provides evidence to support the
beneficial effects of metformin on reducing hepatic steatosis and
inflammation of NAFLD, and these effects are independent of
alterations of adipose tissue phenotype. Mechanistically, metfor-
min actions are attributable to the effects of metformin on
improving hepatocyte fat metabolism and on suppressing hepato-
cyte and macrophage inflammatory responses. As such, metformin
supplementation could be an effective approach for treatment
and/or prevention of obesity-associated NFALD.
Materials and Methods
Animal experiments
C57BL/6J mice were obtained from the Jackson Laboratory
and maintained on a 12:12-h light-dark cycle (lights on at 06:00).
At 5–6 weeks of age, male mice were fed a high-fat diet (HFD,
60% fat calories, 20% protein calories, and 20% carbohydrate
calories) for 12 weeks and treated with metformin (150 mg/kg
body weight/d, solutions in PBS) or PBS via oral gavages for the
last 4 weeks. As additional controls, gender- and age-matched
C57BL/6J mice were fed a low-fat diet (LFD, 10% fat calories,
20% protein calories, and 70% carbohydrate calories) for 12 weeks
and treated with PBS for the last 4 weeks. Both diets are products
of Research Diets, Inc (New Brunswick, NJ) and contain the same
of amount of casein, L-cystein, cellulose, sucrose, soybean oil, and
minerals. However, the HFD contains much more lard but none
corn starch compared with the LFD. During the 12-week feeding/
treatment period, body weight and food intake of the mice were
recorded weekly. After the feeding/treatment regimen, mice were
fasted for 4 hr before sacrifice for collection of blood and tissue
samples [39–41]. Epididymal, mesenteric, and perinephric fat
depots were dissected and weighed as visceral fat content [40].
Liver weight was also recorded. After weighing, part of epididymal
fat was subjected to isolation of stromal vascular cells as described
below. Additional adipose and liver tissue samples were either
fixed and embedded for histological analyses (H&E staining) or
frozen in liquid nitrogen and stored at 280uC for further analyses
[40,42]. Some mice were fasted similarly and used for insulin and
glucose tolerance tests as described below. All animals received
human care and all study protocols were approved by the
Institutional Animal Care and Use Committee of Texas A&M
University.
Insulin and glucose tolerance tests
Mice were fasted for 4 hr and received an intraperitoneal
injection of insulin (1 U/kg body weight) or D-glucose (2 g/kg
body weight). For insulin tolerance tests, blood samples (5 ml) were
collected from the tail vein before and at 15, 30, 45, and 60 min
after the bolus insulin injection. Similarly, for glucose tolerance
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tests, blood samples were collected from the tail vein before and at
30, 60, 90 and 120 min after the glucose bolus injection [43,44].
The levels of plasma glucose were measured using an enzymatic
assay kit (Sigma, St. Louis, MO).
Isolation of stromal vascular cells from adipose tissue
Adipose tissue stromal vascular cells (SVC) were isolated using
the collagenase digestion method as previously described [43,45].
After digestion and centrifugation, the pelleted cells were collected
as SVC and subjected to FACS analyses.
Flow cytometry analysis
Adipose tissue SVC were stained with fluorescence-tagged
antibodies: anti-F4/80, anti-CD11b for macrophages, and anti-
CD11c and anti-CD206 for macrophage inflammatory status as
previously described [46], and subjected to FACS analyses using
BD FACSAria II flow cytometer (BD Biosciences, San Jose,
California, USA) that is operated by Texas A&M Health Science
Center College of Medicine Cell Analysis Facility.
Oil-Red-O staining and immunohistochemical analyses
Frozen liver sections were stained with Oil-Red-O as previously
described [32]. The paraffin-embedded liver and adipose tissue
blocks were cut into sections of 5 mm thickness and stained for the
expression of F4/80 with rabbit anti-F4/80 (1:100) (AbD Serotec,
Raleigh, NC) [43].
Cell culture and treatment
H4IIE cells (rat hepatoma cells) were maintained in high
glucose Dulbecco’s modified eagle medium (DMEM) supplement-
ed with 10% fetal bovine serum, 100 units/ml penicillin and
100 mg/l streptomycin as previously described [28,34]. At 80%
confluence, H4IIE cells were treated with metformin (500 mM) or
PBS in the presence or absence of palmitate (250 mM) for 24 hr to
induce fat deposition. To examine lipid accumulation, the treated
hepatocytes were stained with Oil-Red-O for the last 1 hr. To
determine changes in hepatocyte AMPK and inflammatory
signaling, metformin- or PBS-treated cells were supplemented
with or without LPS (100 ng/ml) for 30 min prior to harvest. Cell
lysates were prepared and used to measure the levels of AMPK,
JNK1, NF-kB p65, phospho-AMPK, phospho-JNK1, and phos-
pho-p65 (Ser536) using Western blot analyses. To analyze
hepatocyte gene expression, the total RNA was prepared from
metformin- or PBS-treated cells and subjected to reverse
transcription and real-time PCR.
Additional to hepatocytes, macrophages were also used to
address a direct anti-inflammatory effect of metformin. Briefly,
bone marrow cells were isolated from the tibias and femurs of
chow diet-fed C57BL/6J mice as previously described [47]. After
differentiation with Iscove’s modified Dulbecco’s medium (IMDM)
containing 10% fetal bovine serum and 15% L929 culture
supernatant for 8 days, bone marrow-derived macrophages
(BMDM) were treated with metformin (500 mM) or PBS for
24 hr in the presence or absence of LPS (100 ng/ml) for the last
30 min. Cell lysates were prepared and used to examine the
inflammatory signaling using Western blot analyses. Some cells
were treated with or without LPS at the same dose for 6 hr prior to
harvest of RNA samples.
Western blots
Lysates were prepared from frozen tissue samples and cultured
cells using the lysis buffer containing 50 mm HEPES (pH 7.4), 1%
Triton X-100, 50 mm sodium pyrophosphate, 0.1 m sodium
fluoride, 10 mm EDTA, 10 mm sodium orthovanadate, 10 mg/ml
aprotinin, 10 mg/ml leupeptin, 2 mm benzamidine, and 2 mm
phenylmethylsulfonyl fluoride. After protein electrophoresis and
transfer, immunoblots were performed using rabbit anti-serum as
primary antibody at a 1:1,000 dilution. The blot was followed by a
1:10,000 dilution of goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody kit (ImmobilonTM Western;
EMD Millipore, Billerica, MA, USA) as previously described
[40]. GAPDH was used as a loading control. The maximum
intensity of each band was quantified using ImageJ software.
Ratios of P-AMPK/AMPK, P-ACC/ACC, Pp46/p46, and Pp65/
p65 were normalized to GAPDH and adjusted relative to the
average of PBS-treated control, which was arbitrarily set as 1 (AU).
RNA isolation, reverse transcription, and real-time PCR
The total RNA was isolated from frozen tissue samples and
cultured/isolated cells. Reverse transcription was performed using
the GoScriptTM Reverse Transcription System (Promega) and
real-time PCR analysis was performed using SYBR Green
(LightCyclerH 480 system; Roche) [28,41,48]. The mRNA levels
were analyzed for ACC1, FAS, CPT1a, SREPB1c, IL-1b, IL-6,
TNFa, arginase 1, adiponectin, and/or resistin in tissue and/or
cell samples. A total of 0.1 mg RNA was used for the
determination. Results were normalized to 18 s ribosomal RNA
as plotted as relative expression to the average of PBS-treated
control, which was set as 1.
Statistical Methods
Numeric data are presented as means 6 SE (standard error).
Two-tailed Student’s t tests were used for statistical analyses.
Differences were considered significant at the P,0.05.
Supporting Information
File S1 Contains Figure S1. FACS analysis of adipose
tissue stromal vascular cells. Male C57BL6/J mice, at 5–6
weeks of age, were fed a high-fat diet (HFD) and treated with
metformin (Met, 150 mg/kg/d, in phosphate-buffered saline
(PBS)) or PBS for the last 4 weeks of HFD feeding (n= 4–6).
After the feeding/treatment regimen, stromal vascular cells (SVC)
were isolated from epididymal fat pads and subjected to FACS
analysis. (A) SVC were included for FACS analyses. (B) SVC
(without staining) were analyzed for APC and FITC. (C) SVC
(with staining) were analyzed for F4/80 (FITC) and CD11b (APC)
expression.
(PDF)
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